MET and non-small cell lung carcinoma: In another recent, small, retrospective study of paired tissue samples from patients with EGFRm advanced NSCLC analyzed using next-generation sequencing (NGS), it was identified that off-target resistance in the first-line setting was higher versus in the later-line setting, with MET amplification the most common off-target acquired mechanism to first-line osimertinib17.